TY - JOUR A2 - Jurisic，弗拉基米尔AU - Bilska，莫妮卡AU - Pawłowska，安娜AU - Zakrzewska，Ewelina AU - 胡齐克，阿加塔AU - Suszczyk，多罗塔AU - Gogacz，马立克AU - Wertel，伊沃娜PY - 2020 DA - 2020 /02/21 TI - Th17细胞和IL-17作为一种新的免疫目标在卵巢癌治疗SP - 8797683 VL - 2020 AB - 卵巢癌（OC）通常确诊时已是晚期，并与预后不良相关。尽管有大量的研究，OC的发病机制仍是未知数。最近的研究表明，免疫系统在OC的发展和传播的作用。的因素和机制的识别参与该过程和它们的调制是用于创建有效的抗肿瘤治疗是至关重要的。我们研究Th17细胞在OC患者的潜在作用（ ñ = 71) by analyzing the frequencies of Th17 cells in three different environments, i.e., peripheral blood (PB), peritoneal fluid (PF), and tissue (Th17 infiltrating cells), and the concentration of IL-17A in plasma and PF of patients in terms of their clinical and prognostic significance. Th17 cells were analyzed by flow cytometry as a percentage of CD4⁺淋巴细胞所表达的IL-17A的细胞内表达。IL-17A在血浆和PF的水平通过ELISA确定。我们的研究结果显示，中Th17细胞的积累肿瘤浸润CD4⁺淋巴细胞（ p < 0.001 相对于PB）。此外，Th17细胞在两个PB和OC患者PF的百分比高于良性肿瘤组显著降低（ ñ = 35). There were no significant differences in the percentage of Th17 cells in PB, PF, and tissue in relation to clinicopathological characteristics of OC patients and survival. The lower percentage of Th17 cells in the PB and PF of OC patients may promote evasion of host immune response by cancer cells. The concentration of IL-17A in plasma of OC patients was higher ( p < 0.0001 ）比，在这两种良性肿瘤和对照组（ ñ = 10). The PF IL-17A level in OC patients was higher ( p < 0.0001 ）高于在妇女以良性卵巢肿瘤，表明其在OC微环境的合成。OC患者生存：在PF更高的IL-17A水平与更长（36.5对比27个月中位数）相关。SN - 1687-8450 UR - https://doi.org/10.1155/2020/8797683 DO - 10.1155 /八百七十九万七千六百八十三分之二千○二十〇JF - 肿瘤学杂志PB的 - Hindawi出版KW - ER -